Amgen Sues Genentech To Shield Avastin Biosimilar
Amgen Inc. filed a suit in California federal court Friday seeking a declaration that 27 patents related to Genentech's cancer treatment Avastin are invalid, unenforceable and aren't infringed by Amgen's biologic,...To view the full article, register now.
Already a subscriber? Click here to view full article